证券代码：600807 证券简称：济南高新 公告编号：临 2023-066 济南高新发展股份有限公司 关于召开 2023 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 投资者可于 2023 年 9 月 12 日(星期二) 至 9 月 18 日(星期一)前登录上证 路演中心网站首页点击"提问预征集"栏目或通过公司邮箱600807@vip.163.com 进行 提问。公司将在说明会上对投资者普遍关注的问题进行回答。 济南高新发展股份有限公司（以下简称"公司"）已于 2023 年 8 月 30 日披 露 2023 年半年度报告，为便于广大投资者更全面深入地了解公司 2023 年半年度 经营成果、财务状况，公司计划于 2023 年 9 月 19 日下午 14:00-15:00 举行 2023 年半年度业绩说明会，就投资者关心的问题进行交流。 一、说明会类型 本次业绩说明会以网络互动形式召开，公司将针对 2023 年半年度的经营成 果及财务指标的具体情况与投资者进行互动交流和沟通，在信息 ...

Financial Performance - The company's operating revenue for the first half of 2023 was ¥401,457,082.69, a decrease of 44.30% compared to ¥720,758,018.97 in the same period last year[18]. - The net profit attributable to shareholders for the first half of 2023 was -¥46,940,056.54, improving from -¥293,179,178.50 in the previous year[18]. - The net cash flow from operating activities was -¥179,221,195.56, compared to -¥168,370,583.08 in the same period last year[18]. - The total assets at the end of the reporting period were ¥3,516,429,516.14, down 12.09% from ¥3,999,911,482.83 at the end of the previous year[18]. - The net assets attributable to shareholders decreased by 16.99% to ¥290,954,034.45 from ¥350,493,511.05 at the end of the previous year[18]. - The basic earnings per share for the first half of 2023 was -¥0.05, compared to -¥0.34 in the same period last year[19]. - The weighted average return on net assets improved to -14.58% from -100.47%, an increase of 85.89 percentage points[20]. - The company reported a decrease in the diluted earnings per share to -¥0.05 from -¥0.34 year-on-year[19]. - The net profit after deducting non-recurring gains and losses was -¥29,434,006.54, compared to -¥45,248,819.86 in the previous year[18]. - The total operating income decreased by 44.30% to CNY 401.46 million compared to the same period last year[46]. - The operating costs also decreased by 47.78% to CNY 277.47 million, primarily due to the divestment of mining operations[48]. - The company reported a net loss of ¥168.68 for Wangsheng Ecology, a 112.55% decrease compared to the previous year's profit of ¥1,344.17, primarily due to increased credit impairment losses[70]. - The company reported a net loss of 18 million RMB for the first half of 2023, with total assets amounting to 42.5 million RMB[107]. - The net loss for the period was reported at 1,640.43 million RMB, indicating a challenging financial environment[156]. - The company recorded a comprehensive loss of 13,583.00 million RMB during the first half of 2023, highlighting ongoing financial difficulties[159]. Market and Industry Insights - The global in vitro diagnostics (IVD) market was valued at $127.4 billion in 2022, with a projected compound annual growth rate (CAGR) of 1.91% until 2027[25]. - China's IVD market grew from ¥45 billion in 2016 to ¥124.3 billion in 2021, maintaining a CAGR of 22.5%[25]. - The independent medical laboratory (ICL) industry in China is expected to reach a market size of ¥51.3 billion by 2026, with a CAGR of 18.2% from 2021 to 2026[26]. - The real estate market is expected to experience a gradual recovery in the second half of 2023, supported by favorable policies and easing financing difficulties[29]. Business Operations and Strategy - The company focuses on the life and health core business, aiming to become a leading service provider in the domestic life and health industry[30]. - The company is committed to continuous product innovation and development in the field of molecular diagnostics and third-party medical testing services[30]. - The landscaping and municipal construction business is providing comprehensive ecological restoration and construction services, contributing to the company's revenue growth[33]. - The company is actively expanding its third-party medical testing services, including COVID-19 nucleic acid testing for enterprises and schools[32]. - The company has developed over 150 types of molecular diagnostic reagents for major infectious diseases, covering 80% of nationally mandated infectious diseases[30]. - The company has developed a new generation of high-throughput fully automated nucleic acid detection systems, enhancing its product offerings in the molecular diagnostics sector[31]. - The company is focusing on expanding its core business in life health, with plans to enhance its industry chain and core competitiveness[72]. - The company is exploring potential mergers and acquisitions to strengthen its market position and diversify its portfolio[156]. Governance and Compliance - The company guarantees the independence of its senior management and financial personnel, ensuring no dual roles in controlled entities[85]. - The company will minimize related party transactions post-restructuring, ensuring compliance with market principles and fair pricing[85]. - The company has established a governance structure to ensure independence and prevent asset and fund occupation[87]. - The company has not disclosed any significant related party transactions during the reporting period[94]. - The company has not reported any major guarantees during the reporting period[98]. - The company has not disclosed any ongoing or unresolved major contracts[97]. - The company has not reported any litigation or arbitration matters that are not disclosed or have subsequent developments[93]. Legal and Litigation Matters - The company is involved in significant litigation matters, including a dispute with Shenzhen Fu'ao Kang Fund Management Co., which has been resolved with the court ruling that the guarantee contract is not enforceable[90]. - A settlement has been reached in the case involving Yang Haoyu and Yong'an Real Estate, with compensation based on a principal amount of CNY 40,258,125, calculated according to the prevailing loan interest rates[90]. - The company is actively pursuing legal actions to recover debts and enforce court rulings[91]. - The company has been involved in multiple legal disputes, indicating ongoing challenges in its financial operations[91]. Shareholder and Capital Structure - The company initiated a private placement of shares at CNY 2.44 per share, aiming to raise up to CNY 400 million to supplement working capital[43]. - The total number of ordinary shareholders at the end of the reporting period is 41,564[104]. - The largest shareholder, Jinan High-tech City Construction Development Co., Ltd., holds 142,307,521 shares, accounting for 16.09% of the total shares[106]. - The company has not experienced any changes in its total share capital or share structure during the reporting period[103]. - The company has suspended the implementation of its stock incentive plan due to an audit report from 2017 that was issued with a disclaimer of opinion[109]. - The company has terminated its stock incentive plan, which was triggered by the audit report, and is currently pausing subsequent share repurchase and cancellation procedures[110]. Financial Position and Assets - The company's total assets decreased to CNY 2,249,414,091.50 from CNY 2,547,040,791.13, reflecting a decline of 11.7%[122]. - Total liabilities decreased to CNY 1,612,753,984.22 from CNY 1,857,040,952.18, a reduction of 13.2%[122]. - The company's equity decreased to CNY 636,660,107.28 from CNY 689,999,838.95, a decline of 7.7%[122]. - The company’s total equity decreased to RMB 796,239,548.77, down 4.5% from RMB 834,074,513.26 at the end of 2022[118]. - The company’s cash and cash equivalents decreased by 65.06% to CNY 272.88 million, mainly due to loan repayments and litigation costs[56]. Research and Development - The company’s research and development expenses decreased by 32.95% to CNY 6.41 million, reflecting reduced investment in R&D[47]. - The company has over 100 patents/software copyrights and multiple medical device registration certificates, showcasing its strong innovation capabilities[38]. Accounting and Financial Reporting - The company’s financial statements are prepared based on the accrual basis of accounting, in accordance with the relevant accounting standards[171]. - The company adheres to the accounting standards, ensuring that the consolidated financial statements accurately reflect its financial position as of June 30, 2023, and the operating results for the first half of 2023[174]. - The company's accounting period follows the calendar year, from January 1 to December 31[175].

证券代码：600807 证券简称：济南高新 公告编号：临2023-063 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 公司于 2023 年 8 月 29日召开第十一届董事会第六次会议、第十一届监事会第四次会议， 审议通过《关于审议公司计提资产减值准备的议案》，为更加客观、公允地反映公司财务状 况和资产价值，根据《企业会计准则》的规定，结合公司实际经营情况和资产现状，公司对 截至 2023 年 6 月 30 日的各类资产进行了全面清查。通过分析、评估，基于谨慎性原则，对 存在减值迹象的相关资产进行减值测试并计提相应的减值准备，计提信用减值损失、合同资 产减值损失等共计 2,454.94 万元，具体情况如下： 一、计提信用减值损失和合同资产减值损失的情况 1、信用减值损失 根据《企业会计准则第 22 号--金融工具确认和计量》及会计政策的相关规定，公司以 预期信用损失为基础，对金融资产进行分类并分别按照其适用的预期信用损失计量方法计提 减值准备并确认信用减值损失。对于存在客观证据表明存在减值，以及其他适用于单项评估 的应 ...

证券代码：600807 证券简称：济南高新 公告编号：临2023-061 济南高新发展股份有限公司 第十一届董事会第六次会议决议公告 表决结果：9 票同意、0 票反对、0 票弃权。 二、审议通过《关于审议公司计提资产减值准备的议案》； 本次计提 2023 年半年度资产减值准备系基于会计谨慎性的原则，符合《企 业会计准则》和相关会计政策的规定，依据充分，符合资产的实际情况。本次计 提资产减值准备后，公司财务报表能够更加公允、客观地反映 2023 年半年度末 的财务状况、资产价值及 2023 年半年度的经营成果。 表决结果：9 票同意、0 票反对、0 票弃权。 三、审议通过《关于审议公司全资子公司债务重组融资的议案》。 表决结果：9 票同意、0 票反对、0 票弃权。 特此公告。 济南高新发展股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 公司第十一届董事会第六次会议于2023年8月29日上午10点，在中国（山东） 自由贸易试验区济南片区舜华街道龙奥北路1577号龙奥天街广场主办公楼1616 会议室，以现场和通讯 ...

经审核，监事会认为： 1、公司 2023 年半年度报告及摘要的编制和审议程序符合有关法律、法规、公司章程和 公司内部管理制度的要求与规定； 2、公司 2023 年半年度报告及摘要的内容和格式符合中国证监会和上海证券交易所的有 关规定，所包含的信息能够真实地反映出公司报告期内经营管理和财务状况等事项，不存在 虚假记载、误导性陈述或重大遗漏； 3、在提出本意见前，未发现参与半年报编制和审议的人员有违反保密规定的行为。 证券代码：600807 证券简称：济南高新 公告编号：临2023-062 济南高新发展股份有限公司 第十一届监事会第四次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 公司第十一届监事会第四次会议于2023年8月29日上午11点，在中国（山东）自由贸易 试验区济南片区舜华街道龙奥北路1577号龙奥天街广场主办公楼1616会议室，以现场方式召 开。应出席会议监事5名，实际出席会议监事5名。公司董事会秘书、财务总监列席了会议， 符合《中华人民共和国公司法》《公司章程》等要求。会议由监事会主席刘洋先生主 ...

证券代码：600807 证券简称：济南高新 公告编号：临 2023-064 济南高新发展股份有限公司 关于全资子公司债务重组融资事项的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 公司全资子公司山东济安企业发展有限公司（简称"济安企业"）以其对公司、 山东永安房地产开发有限公司（简称"永安房地产"）的债权开展债务重组融资业 务，将合计7,452.13万元的债权以4,500万元转让给山东省金融资产管理股份有限公 司（简称"山东金融资产"），相关方按照4,500万元进行执行和解，公司为永安房 地产于和解协议项下的债权提供连带责任保证。 截至2022年12月31日，山东金融资产总资产13,482,843.78万元，净资产 6,660,005.54万元；2022年实现营业收入317,256.28万元，净利润238,656.84万元。 （经审计） 公司于2023年8月29日召开第十一届董事会第六次会议，审议通过《关于审议公 司全资子公司债务重组融资的议案》，为盘活公司低效资产，拓宽公司融资渠道， 提高公司内 ...

Financial Performance - The company's operating revenue for Q1 2023 was CNY 194,033,810.54, representing a decrease of 39.51% compared to the same period last year[4]. - The net profit attributable to shareholders was CNY 6,908,536.44, with a basic and diluted earnings per share of CNY 0.01[4]. - The company reported a net loss of CNY 1,324,225,496.11 in equity, slightly improved from a loss of CNY 1,328,902,246.75 in the previous period[15]. - In Q1 2023, the company reported a net profit of ¥16,497,674.38, a significant recovery from a net loss of ¥129,309,431.30 in Q1 2022[18]. - Operating profit for Q1 2023 was ¥21,569,386.10, compared to an operating loss of ¥119,878,552.89 in the same period last year[18]. - Total revenue from sales and services received was ¥135,151,799.48, down 56.1% from ¥307,591,756.22 in Q1 2022[20]. - Total comprehensive income for Q1 2023 was -¥37,099.91, a significant improvement from -¥100,682,356.23 in Q1 2022[19]. Cash Flow and Liquidity - The net cash flow from operating activities was negative at CNY -134,510,849.16, primarily due to reduced sales collections in the mining business compared to the previous year[8]. - The company experienced a net cash outflow from operating activities of ¥134,510,849.16, worsening from a net outflow of ¥48,062,891.97 in Q1 2022[21]. - Cash and cash equivalents decreased to CNY 481,209,065.45 from CNY 781,095,935.45, representing a decline of 38.4%[13]. - The cash and cash equivalents at the end of Q1 2023 stood at ¥343,964,456.97, a decrease from ¥640,222,839.93 at the beginning of the quarter[22]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 3,772,305,774.16, down 5.69% from the end of the previous year[5]. - Total assets as of March 31, 2023, were CNY 3,772,305,774.16, down from CNY 3,999,911,482.83 at the end of 2022, a decrease of 5.7%[14]. - Total liabilities decreased to CNY 2,939,281,073.97 from CNY 3,165,836,969.57, a reduction of 7.1%[15]. - The company's equity attributable to shareholders decreased to CNY 338,555,149.11 from CNY 350,493,511.05, a decline of 3.4%[15]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 42,981[10]. - The largest shareholder, Jinan High-tech Urban Construction Development Co., Ltd., held 16.09% of the shares, amounting to 142,307,521 shares[10]. Operational Strategy - The company plans to focus on improving operational efficiency and exploring new market opportunities in the upcoming quarters[8]. - The company has no new product launches or significant market expansion strategies mentioned in the report[12]. - The company plans to enhance its market expansion strategies and invest in new technologies to drive future growth[18]. Costs and Expenses - Total operating costs for Q1 2023 were CNY 173,143,939.18, down 45.0% from CNY 315,152,907.71 in Q1 2022[17]. - Research and development expenses increased to ¥4,409,719.95 in Q1 2023, compared to ¥1,889,536.86 in Q1 2022, indicating a focus on innovation[18]. - The company incurred financial expenses of ¥4,973,246.62, which included interest expenses of ¥8,788,544.34[18]. Non-Recurring Items - The company reported non-recurring gains and losses totaling CNY -3,636,113.03, influenced by various factors including government subsidies and other non-operating income[7]. - The weighted average return on net assets was 2.00% for the reporting period[5].

基于谨慎性原则，公司将2023年一季度黄金贸易业务收入确认方式由"总额 法"调整为"净额法"，本次会计差错更正影响公司2023年第一季度的营业收入 和营业成本，不影响净利润，不影响资产负债表及现金流量表的列报。本次会计 差错更正仅影响2023年第一季度报告，不影响公司前期定期报告相关财务数据和 财务指标。 公司于2023年8月18日召开了第十一届董事会第五次临时会议、第十一届监 事会第三次临时会议，审议通过了《关于审议前期会计差错更正的议案》，同意 根据《企业会计准则第28号—会计政策、会计估计变更和差错更正》、《公开发行 证券的公司信息披露编报规则第19号—财务信息的更正及相关披露》、《上海证券 交易所上市公司自律监管指南第1号——公告格式》等相关规定及公司自查的实 际情况，对公司前期会计差错进行更正。该议案无需提交股东大会审议。具体情 况如下： 股票代码：600807 股票简称：济南高新 公告编号：临2023-060 济南高新发展股份有限公司 关于前期会计差错更正的公告 本公司及董事会全体成员保证公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实、准确和完整承担个别及连带责任。 重要内 ...

本次业绩说明会以网络互动形式召开，公司将针对 2022 年度的经营成果及 财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范围内就 投资者普遍关注的问题进行回答。 证券代码：600807 证券简称：济南高新 公告编号：临 2023-030 济南高新发展股份有限公司 二、说明会召开的时间、地点 关于召开 2022 年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 投资者可于 2023 年 5 月 19 日(星期五)至 5 月 25 日(星期四)16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱600807@vip.163.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 济南高新发展股份有限公司（以下简称"公司"）已于 2023 年 4 月 29 日披 露2022年度报告，为便于广大投资者更全面深入地了解公司2022年度经营成果、 财务状况，公司计划于 2023 年 5 月 26 日下午 16:00-17:00 举行 2022 年 ...

Financial Performance - The company achieved a net profit of ¥80,695,350.17 for the fiscal year 2022, with a net profit attributable to shareholders of the parent company amounting to ¥18,353,177.97[6]. - The company's operating revenue for 2022 was approximately ¥1.72 billion, representing a year-over-year increase of 33.96% compared to ¥1.28 billion in 2021[22]. - The net profit attributable to shareholders was approximately ¥18.35 million, a 24.98% increase from ¥14.69 million in 2021[22]. - The net profit after deducting non-recurring gains and losses was approximately -¥19.77 million, a significant decrease of 310.49% compared to ¥9.39 million in 2021[22]. - The total assets decreased by 35.30% to approximately ¥4.00 billion from ¥6.18 billion in 2021[22]. - The weighted average return on equity increased to 4.62%, up 1.61 percentage points from 3.01% in 2021[23]. - The company reported a cash flow from operating activities of approximately -¥521.49 million, an improvement from -¥557.58 million in 2021[22]. - The basic earnings per share remained stable at ¥0.02, unchanged from 2021[23]. - Non-recurring gains amounted to approximately ¥38.12 million in 2022, compared to ¥5.29 million in 2021[29]. - The company experienced a significant decline in net assets attributable to shareholders, which decreased by 20.72% to approximately ¥350.49 million from ¥442.10 million in 2021[22]. Governance and Compliance - The company has received a standard unqualified audit report from Zhongxinghua Certified Public Accountants[5]. - The company’s board of directors and supervisory board members have all attended the board meeting, ensuring the authenticity and completeness of the annual report[4]. - The company has confirmed that there are no non-operating fund occupations by controlling shareholders or related parties[8]. - The company has not provided guarantees in violation of regulatory decision-making procedures[8]. - The company has established a system for managing insider information, effectively preventing insider trading incidents during the reporting period[106]. - The company has revised its governance documents, including the Articles of Association and rules for shareholder meetings, to enhance governance structure[103]. - The company maintains independence from its controlling shareholder in operations, assets, and finances, with no violations reported regarding guarantees or fund occupation[104]. - The company has improved its information disclosure practices, ensuring timely and accurate communication with shareholders[105]. - The company continues to enhance its governance practices to promote healthy and rapid development[106]. - The company has designated specific media outlets for information disclosure, ensuring equal access for all shareholders[105]. Strategic Initiatives - The company plans to focus on expanding its market presence and enhancing its product offerings in the upcoming fiscal year[30]. - The company divested from capital-intensive mining and real estate sectors, enhancing its financial structure and focusing on core business development[33]. - The company is enhancing the operational quality of its health park projects and has initiated the construction of the Huanshan Health Project, a key PPP demonstration project[35]. - The company is leveraging its strong shareholder support and regional advantages to enhance governance and operational capabilities, aiming to become a leading service provider in the life and health industry[40]. - The company plans to continue focusing on its core business in life sciences and biotechnology to ensure sustainable growth[41]. - The company aims to achieve revenue of RMB 1 billion and a cost of RMB 750 million in 2023, with a target of RMB 200 million for period expenses[96]. - The company plans to enhance its core business in life health and biotechnology, focusing on in vitro diagnostics and expanding its product line through increased R&D efforts[96]. - The company will conduct investment and expansion activities, targeting quality enterprises in the IVD and medical device sectors to extend its life health business chain[97]. Market and Industry Insights - The external diagnostic market in China is estimated to reach approximately 6.6 billion USD in 2022, with a projected annual growth rate of 3.8%[37]. - The global in vitro diagnostic market is expected to grow from 127 billion USD in 2022 to 140 billion USD by 2027, at an annual growth rate of 2%[37]. Asset Management and Restructuring - The company completed the transfer of 100% equity of NQM Gold 2 Pty Ltd to an affiliate for a transaction price of 902.8246 million yuan[87]. - The company sold the Golden Dragon mine and related assets to DC Mines Pty Ltd for a cash consideration of 20 million Australian dollars, with additional contingent payments[88]. - The company transferred 100% equity of Jinan Ji'an Industry to related party Shunzheng Investment for a transaction price of 166.2383 million RMB, and Ji'an Industry will no longer be included in the consolidated financial statements after the transfer[163]. - The company transferred 100% equity of NQM Gold 2 Pty Ltd to related party Yurun Gold Co., Ltd. for a transaction price of 902.8246 million RMB, constituting a major asset restructuring[163]. - The company transferred 70% equity of Jinan Jigaohangu to related party Shunzheng Investment for a transaction price of 101.6861 million RMB, and Jigaohangu will no longer be included in the consolidated financial statements after the transfer[163]. Employee and Management Structure - The total number of employees in the parent company and major subsidiaries is 731, with 83 in the parent company and 648 in subsidiaries[130]. - The company has a total of 8 independent directors, contributing to its governance structure[109]. - The total remuneration for directors, supervisors, and senior management amounted to RMB 4.6304 million during the reporting period[118]. - Changes in senior management included the appointment of Lei Xuefeng as Chief Financial Officer and Ren Xiangkang as Board Secretary[119]. Environmental and Social Responsibility - The company does not have an established environmental protection mechanism and did not invest in environmental protection funds during the reporting period[143]. - The company and its subsidiaries are not classified as key polluting units and comply with national environmental laws without any violations reported[144]. - No administrative penalties were imposed on the company due to environmental issues during the reporting period[145]. - The company has not published a separate social responsibility report or ESG report[148]. Legal and Litigation Matters - The company has ongoing significant litigation matters, including a case with Shenzhen Fu'ao Kang Fund Management Co., which confirmed that the guarantee contract is ineffective and not enforceable[158]. - A settlement has been reached in the case involving Yang Haoyu and Yong'an Real Estate, with compensation based on a principal amount of CNY 40,258,125 calculated at the current loan interest rate[159]. - The company is involved in a dispute with Tianye Group and Shanghai Honghao Trading Co., where the court ruled that the company is liable for 20% of Tianye Group's unpaid obligations, amounting to CNY 10 million in principal and interest[159]. - The company has successfully executed a court ruling requiring Jin Hui Fang Yuan Group to pay CNY 174,628,234 plus interest for equity repurchase[160].